Latest Patent Applications News

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Venus Metals Corporation reports compelling gold assay results from its Henderson and Sandstone projects, alongside advancing mining lease applications and maintaining a robust cash position of $12.4 million.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.

EcoGraf Limited advances its vertically integrated battery anode materials business with a significant UFK loan mandate and progress across upstream, midstream, and downstream operations.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Volt Resources exceeded its graphite production goals in Q4 2024, producing over 800 tonnes at its Ukrainian Zavalievsky mine, while progressing development of its Tanzanian Bunyu Graphite Project and refining a novel US-based purification process.

Reward Minerals has completed the acquisition of the Beyondie Potash Plant, positioning itself to advance its innovative potash processing technologies and reduce production costs. The move, funded through a non-dilutive loan extension, marks a significant step toward commercialising its patented SOP recovery methods.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.